Actively Recruiting
Study of Oral PLX-61639 for Patients With SMARCA4-Mutated Advanced or Metastatic Solid Tumors Evaluating Safety and Antitumor Activity
Led by Plexium, Inc. · Updated on 2026-06-12
155
Participants Needed
10
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, how the body processes, and early antitumor effects of PLX-61639 in adults with locally advanced or metastatic solid tumors that have a specific SMARCA4 mutation and who cannot tolerate or have not responded to approved treatments. This is a first-in-human, multicenter study involving participants with relapsed or refractory cancers. The study includes three parts dose escalation, dose optimization, and cohort expansion to find the best dosing and understand the treatment effects. Participants will receive the study drug PLX-61639, an oral medication designed to degrade SMARCA2, taken once daily in 28-day treatment cycles. The treatment continues until the disease progresses, unacceptable side effects occur, or the participant or investigator decides to stop. Each study part has a screening phase lasting up to 28 days to determine eligibility, followed by treatment cycles, an end-of-treatment visit, and a post-treatment follow-up phase. During the study, participants will be closely monitored for side effects and treatment tolerability. Researchers will assess tumor response using imaging and measure pharmacokinetics during the initial cycles. Outcome measures include adverse events, dose-limiting toxicities, treatment discontinuations, and progression-free survival. The study lasts until disease progression or other stopping criteria, with continued safety follow-up after treatment ends.
CONDITIONS
Brief Title
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Research Team
C
Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here